Top

Published in:

29-04-2022 | Multiple Myeloma

Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation

Authors: Matthew J. Pianko, Jonathan L. Golob

Published in: Cancer and Metastasis Reviews | Issue 2/2022

Abstract

Microbiota are essential to normal immune development and there is growing recognition of its importance to human health and disease and deepening understanding of the complexity of host-microbe interactions in the human gut and other tissues. Commensal microbes not only can influence host immunity locally through impacts of bioactive microbial metabolites and direct interactions with epithelial cells and innate immune receptors but also can exert systemic immunomodulatory effects via impacts on host immune cells capable of trafficking beyond the gut. Emerging data suggest microbiota influence the development of multiple myeloma (MM), a malignancy of the immune system derived from immunoglobulin-producing bone marrow plasma cells, through the promotion of inflammation. Superior treatment outcomes for MM correlate with a higher abundance of commensal microbiota capable of influencing inflammatory responses through the production of butyrate. In patients with hematologic malignancies, higher levels of diversity of the gut microbiota correlate with superior outcomes after hematopoietic stem cell transplantation. Correlative data support the impact of commensal microbiota on survival, risk of infection, disease relapse, and graft-versus-host disease (GVHD) after transplant. In this review, we will discuss the current understanding of the role of host-microbe interactions and the inflammatory tumor microenvironment of multiple myeloma, discuss data describing the key role of microbiota in hematopoietic stem cell transplantation for treatment of hematologic malignancies, and highlight several possible concepts for interventions directed at the gut microbiota to influence treatment outcomes.

Human Microbiome Project Consortium. (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486(7402), 207–214. https://doi.org/10.1038/nature11234CrossRef

Ley, R. E., Hamady, M., Lozupone, C., Turnbaugh, P. J., Ramey, R. R., Bircher, J. S., … Gordon, J. I. (2008). Evolution of mammals and their gut microbes. Science, 320(5883), 1647–1651. https://doi.org/10.1126/science.1155725

Bik, E. M. (2016). The hoops, hopes, and hypes of human microbiome research. The Yale journal of biology and medicine, 89(3), 363–373. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27698620. Accessed 3 Jan 2022

Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011CrossRefPubMedPubMedCentral

Sender, R., Fuchs, S., & Milo, R. (2016). Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell, 164(3), 337–340. https://doi.org/10.1016/j.cell.2016.01.013CrossRefPubMed

Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., … Gordon, J. I. (2012). Human gut microbiome viewed across age and geography. Nature, 486(7402), 222–227. https://doi.org/10.1038/nature11053

Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., … Segal, E. (2018). Environment dominates over host genetics in shaping human gut microbiota. Nature, 555(7695), 210–215. https://doi.org/10.1038/nature25973

David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., … Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505(7484), 559–563. https://doi.org/10.1038/nature12820

Iebba, V., Totino, V., Gagliardi, A., Santangelo, F., Cacciotti, F., Trancassini, M., … Schippa, S. (2016). Eubiosis and dysbiosis: The two sides of the microbiota. The new microbiologica, 39(1), 1–12. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26922981. Accessed 3 Jan 2022

10.

Kostic, A. D., Xavier, R. J., & Gevers, D. (2014). The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology, 146(6), 1489–1499. https://doi.org/10.1053/j.gastro.2014.02.009CrossRefPubMed

11.

Dalal, S. R., & Chang, E. B. (2014). The microbial basis of inflammatory bowel diseases. The Journal of clinical investigation, 124(10), 4190–4196. https://doi.org/10.1172/JCI72330CrossRefPubMedPubMedCentral

12.

Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., … Huttenhower, C. (2019). Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 569(7758), 655–662. https://doi.org/10.1038/s41586-019-1237-9

13.

Dehner, C., Fine, R., & Kriegel, M. A. (2019). The microbiome in systemic autoimmune disease: Mechanistic insights from recent studies. Current opinion in rheumatology, 31(2), 201–207. https://doi.org/10.1097/BOR.0000000000000574CrossRefPubMedPubMedCentral

14.

Paun, A., Yau, C., & Danska, J. S. (2017). The influence of the microbiome on type 1 diabetes. The Journal of Immunology. Retrieved from https://www.jimmunol.org/content/198/2/590.short. Accessed 3 Jan 2022

15.

Udayappan, S., Manneras-Holm, L., Chaplin-Scott, A., Belzer, C., Herrema, H., Dallinga-Thie, G. M., … Nieuwdorp, M. (2016). Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ Biofilms Microbiomes, 2, 16009. https://doi.org/10.1038/npjbiofilms.2016.9

16.

Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., … Bäckhed, F. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature medicine, 23(7), 850–858. https://doi.org/10.1038/nm.4345

17.

Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019). The cancer microbiome. Nature reviews. Cancer, 19(7), 371–376. https://doi.org/10.1038/s41568-019-0155-3CrossRefPubMedPubMedCentral

18.

Xavier, J. B., Young, V. B., Skufca, J., Ginty, F., Testerman, T., Pearson, A. T., … Wargo, J. A. (2020). The cancer microbiome: Distinguishing direct and indirect effects requires a systemic view. Trends in cancer research, 6(3), 192–204. https://doi.org/10.1016/j.trecan.2020.01.004

19.

Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018). The gut microbiota influences anticancer immunosurveillance and general health. Nature reviews. Clinical oncology, 15(6), 382–396. https://doi.org/10.1038/s41571-018-0006-2CrossRefPubMed

20.

Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018). The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell, 33(4), 570–580. https://doi.org/10.1016/j.ccell.2018.03.015CrossRefPubMedPubMedCentral

21.

Yu, A. I., & Chen, G. Y. (2021). The gut microbiome and colorectal cancer. In J. Sun (Ed.), Inflammation, Infection, and Microbiome in Cancers: Evidence, Mechanisms, and Implications (pp. 63–96). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-030-67951-4_3

22.

Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., … Zheng, S. (2019). Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 68(6), 1014–1023. https://doi.org/10.1136/gutjnl-2017-315084

23.

Roderburg, C., & Luedde, T. (2014). The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut microbes, 5(4), 441–445. https://doi.org/10.4161/gmic.29599CrossRefPubMed

24.

Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., … Miller, G. (2018). The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer discovery, 8(4), 403–416. https://doi.org/10.1158/2159-8290.CD-17-1134

25.

Portlock, C. S., Hamlin, P. A., Gerecitano, J. F., Noy, A., Palomba, M. L., Walkley, J., … Markowitz, A. J. (2015). A positive prospective trial of antibiotic therapy in advanced stage, non-bulky indolent lymphoma. Tumor Microenviron Ther, 2(1), 14–18. https://doi.org/10.1515/tumor-2015-0001

26.

Wotherspoon, A. C., Doglioni, C., Diss, T. C., Pan, L., Moschini, A., de Boni, M., & Isaacson, P. G. (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. The Lancet, 342(8871), 575–577. https://doi.org/10.1016/0140-6736(93)91409-fCrossRef

27.

Calcinotto, A., Brevi, A., Chesi, M., Ferrarese, R., Garcia Perez, L., Grioni, M., … Bellone, M. (2018). Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature communications, 9(1), 4832. https://doi.org/10.1038/s41467-018-07305-8

28.

Jian, X., Zhu, Y., Ouyang, J., Lei, Q., Xia, J., Zhang, J., … Zhou, W. (2019). Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen recycling bacteria. Blood, 134(Supplement_1), 688–688. https://doi.org/10.1182/blood-2019-125051

29.

Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017). Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia , 19(10), 848–855. Retrieved from https://www.sciencedirect.com/science/article/pii/S1476558617302385. Accessed 3 Jan 2022

30.

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., … Wargo, J. A. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97–103. https://doi.org/10.1126/science.aan4236

31.

Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., … Carbonnel, F. (2017). Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 28(6), 1368–1379. https://doi.org/10.1093/annonc/mdx108

32.

Vetizou, M., Pitt, J. M., Daillere, R., Lepage, P., Waldschmitt, N., Flament, C., … Zitvogel, L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350(6264), 1079–1084. https://doi.org/10.1126/science.aad1329

33.

Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., … Wolchok, J. D. (2016). Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature communications, 7, 10391. https://doi.org/10.1038/ncomms10391

34.

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., … Goldszmid, R. S. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 342(6161), 967–970. https://doi.org/10.1126/science.1240527

35.

Paulos, C. M., Wrzesinski, C., Kaiser, A., Hinrichs, C. S., Chieppa, M., Cassard, L., … Restifo, N. P. (2007). Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. The Journal of clinical investigation, 117(8), 2197–2204. https://doi.org/10.1172/JCI32205

36.

Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., … Xavier, J. B. (2020). The gut microbiota is associated with immune cell dynamics in humans. Nature, 588(7837), 303–307. https://doi.org/10.1038/s41586-020-2971-8

37.

Honda, K., & Littman, D. R. (2016). The microbiota in adaptive immune homeostasis and disease. Nature, 535(7610), 75–84. https://doi.org/10.1038/nature18848CrossRefPubMed

38.

Al-Asmakh, M., & Zadjali, F. (2015). Use of germ-free animal models in microbiota-related research. Journal of microbiology and biotechnology, 25(10), 1583–1588. https://doi.org/10.4014/jmb.1501.01039CrossRefPubMed

39.

Johansson, M. E. V., Jakobsson, H. E., Holmén-Larsson, J., Schütte, A., Ermund, A., Rodríguez-Piñeiro, A. M., … Hansson, G. C. (2015). Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2015.10.007

40.

Hapfelmeier, S., Lawson, M. A. E., Slack, E., Kirundi, J. K., Stoel, M., Heikenwalder, M., … Macpherson, A. J. (2010). Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science, 328(5986), 1705–1709. https://doi.org/10.1126/science.1188454

41.

Spiljar, M., Merkler, D., & Trajkovski, M. (2017). The immune system bridges the gut microbiota with systemic energy homeostasis: Focus on TLRs, mucosal barrier, and SCFAs. Frontiers in immunology, 8, 1353. https://doi.org/10.3389/fimmu.2017.01353CrossRefPubMedPubMedCentral

42.

Ostman, S., Rask, C., Wold, A. E., Hultkrantz, S., & Telemo, E. (2006). Impaired regulatory T cell function in germ-free mice. European journal of immunology, 36(9), 2336–2346. https://doi.org/10.1002/eji.200535244CrossRefPubMed

43.

Abt, M. C., Osborne, L. C., Monticelli, L. A., Doering, T. A., Alenghat, T., Sonnenberg, G. F., … Artis, D. (2012). Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity, 37(1), 158–170. https://doi.org/10.1016/j.immuni.2012.04.011

44.

Goodman, A. L., Kallstrom, G., Faith, J. J., Reyes, A., Moore, A., Dantas, G., & Gordon, J. I. (2011). Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proceedings of the National Academy of Sciences of the United States of America, 108(15), 6252–6257. https://doi.org/10.1073/pnas.1102938108CrossRefPubMedPubMedCentral

45.

Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., … Littman, D. R. (2009). Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell, 139(3), 485–498. https://doi.org/10.1016/j.cell.2009.09.033

46.

Muranski, P., & Restifo, N. P. (2013). Essentials of Th17 cell commitment and plasticity. Blood, 121(13), 2402–2414. https://doi.org/10.1182/blood-2012-09-378653CrossRefPubMedPubMedCentral

47.

McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., … Leach, S. D. (2014). Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer cell, 25(5), 621–637. https://doi.org/10.1016/j.ccr.2014.03.014

48.

Tartour, E., Fossiez, F., Joyeux, I., Galinha, A., Gey, A., Claret, E., … Sautès-Fridman, C. (1999). Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer research, 59(15), 3698–3704. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10446984. Accessed 3 Jan 2022

49.

Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. The Journal of experimental medicine, 206(7), 1457–1464. jem.20090207 [pii] https://doi.org/10.1084/jem.20090207

50.

Noonan, K., Marchionni, L., Anderson, J., Pardoll, D., Roodman, G. D., & Borrello, I. (2010). A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood, 116(18), 3554–3563. https://doi.org/10.1182/blood-2010-05-283895CrossRefPubMedPubMedCentral

51.

Baxter, N. T., Schmidt, A. W., Venkataraman, A., Kim, K. S., Waldron, C., Schmidt, T. M., & Blaser, M. J. (2019). Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. mBio, 10(1). https://doi.org/10.1128/mBio.02566-18

52.

Davis, J. A., Collier, F., Mohebbi, M., Pasco, J. A., Shivappa, N., Hébert, J. R., … Loughman, A. (2021). The associations of butyrate-producing bacteria of the gut microbiome with diet quality and muscle health. Gut Microbiome, 2(e2), 1–36. https://doi.org/10.1017/gmb.2021.2

53.

Thangaraju, M., Cresci, G. A., Liu, K., Ananth, S., Gnanaprakasam, J. P., Browning, D. D., … Ganapathy, V. (2009). GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer research, 69(7), 2826–2832. https://doi.org/10.1158/0008-5472.CAN-08-4466

54.

Wu, J., Zhou, Z., Hu, Y., & Dong, S. (2012). Butyrate-induced GPR41 activation inhibits histone acetylation and cell growth. Yi chuan xue bao [Journal of genetics and genomics], 39(8), 375–384. https://doi.org/10.1016/j.jgg.2012.05.008CrossRef

55.

Padilla, J., Leung, E., & Phipps, R. P. (2002). Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clinical immunology, 103(1), 22–33. https://doi.org/10.1006/clim.2001.5181CrossRefPubMed

56.

Garcia-Bates, T. M., Bernstein, S. H., & Phipps, R. P. (2008). Peroxisome proliferator-activated receptor γ overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-0457CrossRefPubMedPubMedCentral

57.

Molitor, J. A., Walker, W. H., Doerre, S., Ballard, D. W., & Greene, W. C. (1990). NF-kappa B: A family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proceedings of the National Academy of Sciences of the United States of America, 87(24), 10028–10032. https://doi.org/10.1073/pnas.87.24.10028CrossRefPubMedPubMedCentral

58.

Guilloteau, P., Martin, L., Eeckhaut, V., Ducatelle, R., Zabielski, R., & Van Immerseel, F. (2010). From the gut to the peripheral tissues: The multiple effects of butyrate. Nutrition research reviews, 23(2), 366–384. https://doi.org/10.1017/S0954422410000247CrossRefPubMed

59.

Segain, J.-P. (2000). Butyrate inhibits inflammatory responses through NFkappa B inhibition: Implications for Crohn’s disease. Gut. https://doi.org/10.1136/gut.47.3.397CrossRefPubMedPubMedCentral

60.

Lee, C., Kim, B. G., Kim, J. H., Chun, J., Im, J. P., & Kim, J. S. (2017). Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. International immunopharmacology, 51, 47–56. https://doi.org/10.1016/j.intimp.2017.07.023CrossRefPubMed

61.

Karin, M. (2006). Nuclear factor-κB in cancer development and progression. Nature. https://doi.org/10.1038/nature04870CrossRefPubMed

62.

Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., … Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), 446–450. https://doi.org/10.1038/nature12721

63.

Martin-Gallausiaux, C., Béguet-Crespel, F., Marinelli, L., Jamet, A., Ledue, F., Blottière, H. M., & Lapaque, N. (2018). Butyrate produced by gut commensal bacteria activates TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial cells. Scientific reports, 8(1), 9742. https://doi.org/10.1038/s41598-018-28048-yCrossRefPubMedPubMedCentral

64.

Kim, M., Qie, Y., Park, J., & Kim, C. H. (2016). Gut microbial metabolites fuel host antibody responses. Cell host & microbe, 20(2), 202–214. https://doi.org/10.1016/j.chom.2016.07.001CrossRef

65.

Wu, W., Sun, M., Chen, F., Cao, A. T., Liu, H., Zhao, Y., … Cong, Y. (2017). Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal immunology, 10(4), 946–956. https://doi.org/10.1038/mi.2016.114

66.

Bachem, A., Makhlouf, C., Binger, K. J., de Souza, D. P., Tull, D., Hochheiser, K., … Bedoui, S. (2019). Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T cells. Immunity, 51(2), 285-297.e5. https://doi.org/10.1016/j.immuni.2019.06.002

67.

Kawasaki, T., & Kawai, T. (2014). Toll-like receptor signaling pathways. Frontiers in immunology, 5, 461. https://doi.org/10.3389/fimmu.2014.00461CrossRefPubMedPubMedCentral

68.

Broz, P., & Dixit, V. M. (2016). Inflammasomes: Mechanism of assembly, regulation and signalling. Nature reviews. Immunology, 16(7), 407–420. https://doi.org/10.1038/nri.2016.58CrossRefPubMed

69.

Chassaing, B., Ley, R. E., & Gewirtz, A. T. (2014). Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. Gastroenterology, 147(6), 1363–77.e17. https://doi.org/10.1053/j.gastro.2014.08.033CrossRefPubMed

70.

Chen, G. Y. (2017). Regulation of the gut microbiome by inflammasomes. Free radical biology & medicine, 105, 35–40. https://doi.org/10.1016/j.freeradbiomed.2016.11.011CrossRef

71.

Levy, M., Thaiss, C. A., Zeevi, D., Dohnalová, L., Zilberman-Schapira, G., Mahdi, J. A., … Elinav, E. (2015). Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell, 163(6), 1428–1443. https://doi.org/10.1016/j.cell.2015.10.048

72.

Zhao, Y., Chen, F., Wu, W., Sun, M., Bilotta, A. J., Yao, S., … Cong, Y. (2018). GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunology. https://doi.org/10.1038/mi.2017.118

73.

Novick, D., Kim, S., Kaplanski, G., & Dinarello, C. A. (2013). Interleukin-18, more than a Th1 cytokine. Seminars in immunology, 25(6), 439–448. https://doi.org/10.1016/j.smim.2013.10.014CrossRefPubMed

74.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

75.

Hofbauer, D., Mougiakakos, D., Broggini, L., Zaiss, M., Büttner-Herold, M., Bach, C., … Bruns, H. (2021). β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity. https://doi.org/10.1016/j.immuni.2021.07.002

76.

Li, Y., Li, N., Yan, Z., Li, H., Chen, L., Zhang, Z., … Li, Z. (2016). Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma. Hematology , 21(3), 144–151. https://doi.org/10.1179/1607845415Y.0000000029

77.

Zhao, X., Hua, M., Yan, S., Yu, J., Han, F., Zhong, C., … Ma, D. (2018). The genetic polymorphisms of NLRP3 inflammasome associated with T helper cells in patients with multiple myeloma. Journal of immunology research, 2018, 7569809. https://doi.org/10.1155/2018/7569809

78.

Macpherson, A. J., McCoy, K. D., Johansen, F. E., & Brandtzaeg, P. (2007). The immune geography of IgA induction and function. Mucosal Immunology, 2008(1), 11–22. PMID: 19079156.CrossRef

79.

Chiba, T., Honjo, T., & Fagarasan, S. (2004). Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proceedings of the. Retrieved from https://www.pnas.org/content/101/7/1981.short. Accessed 3 Jan 2022

80.

Suzuki, K., & Nakajima, A. (2014). New aspects of IgA synthesis in the gut. International immunology, 26(9), 489–494. https://doi.org/10.1093/intimm/dxu059CrossRefPubMed

81.

SEER, National Cancer Institute. (n.d.). SEER cancer stat facts: Myeloma. National Cancer Institute. Bethesda, MD. SEER Cancer Stat Facts: Myeloma. Retrieved September 19, 2020, from https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 3 Jan 2022

82.

Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., … Munshi, N. (2018). Genomic patterns of progression in smoldering multiple myeloma. Nature communications, 9(1), 3363. https://doi.org/10.1038/s41467-018-05058-y

83.

Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., … Maura, F. (2021). Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature communications, 12(1), 1861. https://doi.org/10.1038/s41467-021-22140-0

84.

Maura, F., Bolli, N., Angelopoulos, N., Dawson, K. J., Leongamornlert, D., Martincorena, I., … Campbell, P. J. (2019). Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nature communications, 10(1), 3835. https://doi.org/10.1038/s41467-019-11680-1

85.

Ferrucci, L., & Fabbri, E. (2018). Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nature reviews. Cardiology, 15(9), 505–522. https://doi.org/10.1038/s41569-018-0064-2CrossRefPubMedPubMedCentral

86.

Leonardi, G. C., Accardi, G., Monastero, R., Nicoletti, F., & Libra, M. (2018). Ageing: From inflammation to cancer. Immunity & ageing: I & A, 15, 1. https://doi.org/10.1186/s12979-017-0112-5CrossRef

87.

Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013). The interleukin-1 family: Back to the future. Immunity, 39(6), 1003–1018. https://doi.org/10.1016/j.immuni.2013.11.010CrossRefPubMedPubMedCentral

88.

Kovtonyuk, L. V., Caiado, F., Garcia-Martin, S., Manz, E.-M., Helbling, P., Takizawa, H., … Manz, M. G. (2022). IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. Blood, 139(1), 44–58. https://doi.org/10.1182/blood.2021011570

89.

Jaiswal, S., & Ebert, B. L. (2019). Clonal hematopoiesis in human aging and disease. Science, 366(6465). https://doi.org/10.1126/science.aan4673

90.

Zheng, M. M., Zhang, Z., Bemis, K., Belch, A. R., Pilarski, L. M., Shively, J. E., & Kirshner, J. (2013). The systemic cytokine environment is permanently altered in multiple myeloma. PLoS ONE, 8(3), e58504. https://doi.org/10.1371/journal.pone.0058504CrossRefPubMedPubMedCentral

91.

Guillerey, C., Nakamura, K., Vuckovic, S., Hill, G. R., & Smyth, M. J. (2016). Immune responses in multiple myeloma: Role of the natural immune surveillance and potential of immunotherapies. Cellular and molecular life sciences: CMLS, 73(8), 1569–1589. https://doi.org/10.1007/s00018-016-2135-z. Accessed 3 Jan 2022

92.

Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017). Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: The role of cytokines in multiple myeloma. Mediators of inflammation, 2017, 1852517. https://doi.org/10.1155/2017/1852517CrossRefPubMedPubMedCentral

93.

Chen, L., Sun, M., Wu, W., Yang, W., Huang, X., Xiao, Y., … Cong, Y. (2019). Microbiota metabolite butyrate differentially regulates Th1 and Th17 cells’ differentiation and function in induction of colitis. Inflammatory bowel diseases, 25(9), 1450–1461. https://doi.org/10.1093/ibd/izz046

94.

Voorhees, P. M., Manges, R. F., Sonneveld, P., Jagannath, S., Somlo, G., Krishnan, A., … Thomas, S. K. (2013). A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British journal of haematology, 161(3), 357–366. https://doi.org/10.1111/bjh.12266

95.

San-Miguel, J., Bladé, J., Shpilberg, O., Grosicki, S., Maloisel, F., Min, C.-K., … Others. (2014). Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti--IL-6) in multiple myeloma. Blood, The Journal of the American Society of Hematology, 123(26), 4136–4142. Retrieved from https://ashpublications.org/blood/article-abstract/123/26/4136/32785

96.

Kurzrock, R., Voorhees, P. M., Casper, C., Furman, R. R., Fayad, L., Lonial, S., … van Rhee, F. (2013). A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical cancer research: an official journal of the American Association for Cancer Research, 19(13), 3659–3670. https://doi.org/10.1158/1078-0432.CCR-12-3349

97.

Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Witzig, T. E., Moon-Tasson, L. L., Dinarello, C. A., & Donovan, K. A. (2016). Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. American journal of hematology, 91(6), 571–574. https://doi.org/10.1002/ajh.24352CrossRefPubMed

98.

Pianko, M. J., Devlin, S. M., Littmann, E. R., Chansakul, A., Mastey, D., Salcedo, M., … Lesokhin, A. M. (2019). Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood advances, 3(13), 2040–2044. https://doi.org/10.1182/bloodadvances.2019032276

99.

Shah, U., Derkach, A., Adintori, P., Cross, J., Maclachlan, K., Mailankody, S., … Lesokhin, A. (2021). P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets. Clinical lymphoma, myeloma & leukemia, 21, S61. https://doi.org/10.1016/s2152-2650(21)02176-5

100.

Jian, X., Zhu, Y., Ouyang, J., Wang, Y., Lei, Q., Xia, J., … Zhou, W. (2020). Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome, 8(1), 74. https://doi.org/10.1186/s40168-020-00854-5

101.

Drayson, M. T., Bowcock, S., Planche, T., Iqbal, G., Pratt, G., Yong, K., … TEAMM Trial Management Group and Trial Investigators. (2019). Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The lancet oncology, 20(12), 1760–1772. https://doi.org/10.1016/S1470-2045(19)30506-6

102.

Albrich, W. C., & Boggian, K. (2020, February). Levofloxacin prophylaxis in patients with myeloma. The lancet oncology. https://doi.org/10.1016/S1470-2045(20)30008-5

103.

Teh, B. W., Harrison, S. J., Worth, L. J., Thursky, K. A., & Slavin, M. A. (2020, February). Levofloxacin prophylaxis in patients with myeloma. The lancet oncology. https://doi.org/10.1016/S1470-2045(19)30824-1

104.

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillere, R., Hannani, D., … Zitvogel, L. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 342(6161), 971–976. https://doi.org/10.1126/science.1240537

105.

Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., … Gajewski, T. F. (2018). The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. https://doi.org/10.1126/science.aao3290

106.

El Jurdi, N., Filali-Mouhim, A., Salem, I., Retuerto, M., Dambrosio, N. M., Baer, L., … de Lima, M. (2019). Gastrointestinal microbiome and mycobiome changes during autologous transplantation for multiple myeloma: Results of a prospective pilot study. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 25(8), 1511–1519. https://doi.org/10.1016/j.bbmt.2019.04.007

107.

Holler, E., Butzhammer, P., Schmid, K., Hundsrucker, C., Koestler, J., Peter, K., … Oefner, P. J. (2014). Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 20(5), 640–645. https://doi.org/10.1016/j.bbmt.2014.01.030

108.

Taur, Y., Xavier, J. B., Lipuma, L., Ubeda, C., Goldberg, J., Gobourne, A., … Pamer, E. G. (2012). Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 55(7), 905–914. https://doi.org/10.1093/cid/cis580

109.

Golob, J. L., Pergam, S. A., Srinivasan, S., Fiedler, T. L., Liu, C., Garcia, K., … Fredricks, D. N. (2017). Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 65(12), 1984–1991. https://doi.org/10.1093/cid/cix699

110.

Taur, Y., Jenq, R. R., Perales, M. A., Littmann, E. R., Morjaria, S., Ling, L., … Pamer, E. G. (2014). The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood, 124(7), 1174–1182. https://doi.org/10.1182/blood-2014-02-554725

111.

Jenq, R. R., Taur, Y., Devlin, S. M., Ponce, D. M., Goldberg, J. D., Ahr, K. F., … van den Brink, M. R. (2015). Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 21(8), 1373–1383. https://doi.org/10.1016/j.bbmt.2015.04.016

112.

Shono, Y., Docampo, M. D., Peled, J. U., Perobelli, S. M., Velardi, E., Tsai, J. J., … Jenq, R. R. (2016). Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Science translational medicine, 8(339), 339ra71. https://doi.org/10.1126/scitranslmed.aaf2311

113.

Hidaka, D., Hayase, E., Shiratori, S., Hasegawa, Y., Ishio, T., Tateno, T., … Teshima, T. (2018). The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation. Clinical transplantation, 32(9), e13361. https://doi.org/10.1111/ctr.13361

114.

Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., … van den Brink, M. R. M. (2017). Intestinal microbiota and relapse after hematopoietic-cell transplantation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 35(15), 1650–1659. https://doi.org/10.1200/JCO.2016.70.3348

115.

Ubeda, C., Taur, Y., Jenq, R. R., Equinda, M. J., Son, T., Samstein, M., … Pamer, E. G. (2010). Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. The Journal of clinical investigation, 120(12), 4332–4341. https://doi.org/10.1172/JCI43918

116.

Haak, B. W., Littmann, E. R., Chaubard, J.-L., Pickard, A. J., Fontana, E., Adhi, F., … Taur, Y. (2018). Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood, 131(26), 2978–2986. https://doi.org/10.1182/blood-2018-01-828996

117.

Harris, B., Morjaria, S. M., Littmann, E. R., Geyer, A. I., Stover, D. E., Barker, J. N., … Pamer, E. G. (2016). Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. American journal of respiratory and critical care medicine, 194(4), 450–463. https://doi.org/10.1164/rccm.201507-1491OC

118.

Peled, J. U., Gomes, A. L. C., Devlin, S. M., Littmann, E. R., Taur, Y., Sung, A. D., … van den Brink, M. R. M. (2020). Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. The New England journal of medicine, 382(9), 822–834. https://doi.org/10.1056/NEJMoa1900623

119.

Stoma, I., Karpov, I., Milanovich, N., Uss, A., & Iskrov, I. (2016). Risk factors for mortality in patients with bloodstream infections during the pre-engraftment period after hematopoietic stem cell transplantation. Blood research, 51(2), 102–106. https://doi.org/10.5045/br.2016.51.2.102CrossRefPubMedPubMedCentral

120.

Trecarichi, E. M., Pagano, L., Candoni, A., Pastore, D., Cattaneo, C., Fanci, R., … HeMABIS Registry—SEIFEM Group, Italy. (2015). Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 21(4), 337–343. https://doi.org/10.1016/j.cmi.2014.11.022

121.

Averbuch, D., Tridello, G., Hoek, J., Mikulska, M., Akan, H., Yaňez San Segundo, L., … Others. (2017). Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: Intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 65(11), 1819–1828. Retrieved from https://academic.oup.com/cid/article-abstract/65/11/1819/4036247. Accessed 3 Jan 2022

122.

Storb, R., Prentice, R. L., Buckner, C. D., Clift, R. A., Appelbaum, F., Deeg, J., … Thomas, E. D. (1983). Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. The New England journal of medicine, 308(6), 302–307. https://doi.org/10.1056/NEJM198302103080602

123.

Cruciani, M., Rampazzo, R., Malena, M., Lazzarini, L., Todeschini, G., Messori, A., & Concia, E. (1996). Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 23(4), 795–805. https://doi.org/10.1093/clinids/23.4.795

124.

Engels, E. A., Lau, J., & Barza, M. (1998). Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology, 16(3), 1179–1187. https://doi.org/10.1200/JCO.1998.16.3.1179CrossRef

125.

Nagatomo, A., Watanabe, K., Kunikane, H., Okamoto, H., & Kunitoh, H. (1998). A randomized controled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacterial infection during chemotherapy for lung cancer. Lung cancer , 19(2), 121–125. Retrieved from https://www.sciencedirect.com/science/article/pii/S0169500297000871?casa_token=rueotu1UrxQAAAAA:GFf46QwLznRrllvqNVW7dqcS0VnozNfQ2jHNdJsIj9oTJp7SCK4hBG7QCAOzcVcG79gIzxoy. Accessed 3 Jan 2022

126.

Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Stella Dionisi, M., Martinelli, G., … Del Favero, A. (2005). Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa044097

127.

Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., … Stanley, A. (2005). Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine. https://doi.org/10.1056/nejmoa050078

128.

Gafter-Gvili, A., Fraser, A., Paul, M., & Leibovici, L. (2005). Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of Internal Medicine, 142(12 Pt 1), 979–995. https://doi.org/10.7326/0003-4819-142-12_part_1-200506210-00008CrossRefPubMed

129.

Kimura, S.-I., Akahoshi, Y., Nakano, H., Ugai, T., Wada, H., Yamasaki, R., … Kanda, Y. (2014). Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. The Journal of infection, 69(1), 13–25. https://doi.org/10.1016/j.jinf.2014.02.013

130.

Khosravi, A., Yáñez, A., Price, J. G., Chow, A., Merad, M., Goodridge, H. S., & Mazmanian, S. K. (2014). Gut microbiota promote hematopoiesis to control bacterial infection. Cell host & microbe, 15(3), 374–381. https://doi.org/10.1016/j.chom.2014.02.006CrossRef

131.

Josefsdottir, K. S., Baldridge, M. T., Kadmon, C. S., & King, K. Y. (2017). Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota. Blood, 129(6), 729–739. https://doi.org/10.1182/blood-2016-03-708594CrossRefPubMedPubMedCentral

132.

Alonso, C. D., Treadway, S. B., Hanna, D. B., Huff, C. A., Neofytos, D., Carroll, K. C., & Marr, K. A. (2012). Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America, 54(8), 1053–1063. https://doi.org/10.1093/cid/cir1035CrossRef

133.

Yan, H., Baldridge, M. T., & King, K. Y. (2018). Hematopoiesis and the bacterial microbiome. Blood, 132(6), 559–564. https://doi.org/10.1182/blood-2018-02-832519CrossRefPubMedPubMedCentral

134.

Staffas, A., Burgos da Silva, M., Slingerland, A. E., Lazrak, A., Bare, C. J., Holman, C. D., … van den Brink, M. R. M. (2018). Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone marrow transplantation in mice. Cell host & microbe, 23(4), 447-457.e4. https://doi.org/10.1016/j.chom.2018.03.002

135.

Stoma, I., Littmann, E. R., Peled, J. U., Giralt, S., van den Brink, M. R. M., Pamer, E. G., & Taur, Y. (2021). Compositional flux within the intestinal microbiota and risk for bloodstream infection with gram-negative bacteria. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America, 73(11), e4627–e4635. https://doi.org/10.1093/cid/ciaa068CrossRef

136.

Donskey, C. J., Chowdhry, T. K., Hecker, M. T., Hoyen, C. K., Hanrahan, J. A., Hujer, A. M., … Rice, L. B. (2000). Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. The New England journal of medicine, 343(26), 1925–1932. https://doi.org/10.1056/NEJM200012283432604

137.

Tamburini, F. B., Andermann, T. M., Tkachenko, E., Senchyna, F., Banaei, N., & Bhatt, A. S. (2018). Precision identification of diverse bloodstream pathogens in the gut microbiome. Nature medicine, 24(12), 1809–1814. https://doi.org/10.1038/s41591-018-0202-8CrossRefPubMedPubMedCentral

138.

Caballero, S., Kim, S., Carter, R. A., Leiner, I. M., Sušac, B., Miller, L., … Pamer, E. G. (2017). Cooperating commensals restore colonization resistance to vancomycin-resistant Enterococcus faecium. Cell host & microbe, 21(5), 592-602.e4. https://doi.org/10.1016/j.chom.2017.04.002

139.

Gilmore, M. S., Clewell, D. B., Ike, Y., & Shankar, N. (Eds.). (2014). Enterococci: From commensals to leading causes of drug resistant infection. Boston: Massachusetts Eye and Ear Infirmary. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24649510. Accessed 3 Jan 2022

140.

Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., … Pamer, E. G. (2015). Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature, 517(7533), 205–208. https://doi.org/10.1038/nature13828

141.

Miltiadous, O., Waters, N. R., Andrlova, H., Dai, A., Nguyen, C. L., Burgos da Silva, M., … van den Brink, M. R. M. (2022). Early intestinal microbial features are associated with CD4 T cell recovery after allogeneic hematopoietic transplant. Blood. https://doi.org/10.1182/blood.2021014255

142.

Centers for Disease Control and Prevention, Infectious Disease Society of America, & American Society of Blood and Marrow Transplantation. (2000). Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 49(RR-10), 1–125, CE1–7. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11718124. Accessed 3 Jan 2022

143.

Maakaron, J. E., Liscynesky, C., Boghdadly, Z. E., Huang, Y., Agyeman, A., Brammer, J., … Jaglowski, S. M. (2020). Fluoroquinolone prophylaxis in autologous stem cell transplantation: Worthy of a second look. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 26(8), e198–e201. https://doi.org/10.1016/j.bbmt.2020.03.027

144.

Rashidi, A., Wangjam, T., Bhatt, A. S., Weisdorf, D. J., Holtan, S. G., & Investigators, B. M. T. C. T. N. (2018). Antibiotic practice patterns in hematopoietic cell transplantation: A survey of blood and marrow transplant clinical trials network centers. American journal of hematology, 93(11), E348–E350. https://doi.org/10.1002/ajh.25236CrossRefPubMedPubMedCentral

145.

Arai, S., Arora, M., Wang, T., Spellman, S. R., He, W., Couriel, D. R., … Pavletic, S. Z. (2015). Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: A report from the center for international blood and marrow transplant research. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 21(2), 266–274. https://doi.org/10.1016/j.bbmt.2014.10.021

146.

Jacobsohn, D. A., & Vogelsang, G. B. (2007). Acute graft versus host disease. Orphanet journal of rare diseases, 2, 35. https://doi.org/10.1186/1750-1172-2-35CrossRefPubMedPubMedCentral

147.

Storb, R., Gyurkocza, B., Storer, B. E., Maloney, D. G., Sorror, M. L., Mielcarek, M., … Sandmaier, B. M. (2013). Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: Predicting acute graft-versus-host disease and graft-versus-tumor effects. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 19(5), 792–798. https://doi.org/10.1016/j.bbmt.2013.02.006

148.

Sun, Y., Tawara, I., Toubai, T., & Reddy, P. (2007). Pathophysiology of acute graft-versus-host disease: Recent advances. Translational research: The journal of laboratory and clinical medicine, 150(4), 197–214. https://doi.org/10.1016/j.trsl.2007.06.003CrossRef

149.

Stein-Thoeringer, C. K., Nichols, K. B., Lazrak, A., Docampo, M. D., Slingerland, A. E., Slingerland, J. B., … van den Brink, M. R. M. (2019). Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science (New York, N.Y.), 366(6469), 1143–1149. https://doi.org/10.1126/science.aax3760

150.

Connell, M. S., & Wilson, R. (1965). The treatment of x-irradiated germfree CFW and C3H mice with isologous and homologous bone marrow. Life sciences, 4, 721–729. https://doi.org/10.1016/0024-3205(65)90011-1CrossRefPubMed

151.

Jones, J. M., Wilson, R., & Bealmear, P. M. (1971). Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiation research, 45(3), 577–588. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/4396814. Accessed 3 Jan 2022

152.

Bealmear, P. M., Mirand, E. A., & Holtermann, O. A. (1983). Modification of graft-vs-host disease following bone marrow transplantation in germfree mice. Progress in clinical and biological research, 132C, 409–421. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/6227014. Accessed 3 Jan 2022

153.

Bauer, H., Horowitz, R. E., Levenson, S. M., & Popper, H. (1963). The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. The American journal of pathology, 42, 471–483. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13966929. Accessed 3 Jan 2022

154.

Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012). Interactions between the microbiota and the immune system. Science, 336(6086), 1268–1273. https://doi.org/10.1126/science.1223490CrossRefPubMedPubMedCentral

155.

Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nature reviews. Immunology, 9(5), 313–323. https://doi.org/10.1038/nri2515CrossRefPubMedPubMedCentral

156.

Fredricks, D. N. (2019). The gut microbiota and graft-versus-host disease. The Journal of clinical investigation, 129(5), 1808–1817. https://doi.org/10.1172/JCI125797CrossRefPubMedPubMedCentral

157.

Gerbitz, A., Schultz, M., Wilke, A., Linde, H.-J., Schölmerich, J., Andreesen, R., & Holler, E. (2004). Probiotic effects on experimental graft-versus-host disease: Let them eat yogurt. Blood, 103(11), 4365–4367. https://doi.org/10.1182/blood-2003-11-3769CrossRefPubMed

158.

Weber, D., Jenq, R. R., Peled, J. U., Taur, Y., Hiergeist, A., Koestler, J., … Holler, E. (2017). Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 23(5), 845–852. https://doi.org/10.1016/j.bbmt.2017.02.006

159.

Weber, D., Oefner, P. J., Dettmer, K., Hiergeist, A., Koestler, J., Gessner, A., … Holler, E. (2016). Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone marrow transplantation, 51(8), 1087–1092. https://doi.org/10.1038/bmt.2016.66

160.

Romick-Rosendale, L. E., Haslam, D. B., Lane, A., Denson, L., Lake, K., Wilkey, A., … Davies, S. M. (2018). Antibiotic exposure and reduced short chain fatty acid production after hematopoietic stem cell transplant. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 24(12), 2418–2424. https://doi.org/10.1016/j.bbmt.2018.07.030

161.

Markey, K. A., Schluter, J., Gomes, A. L. C., Littmann, E. R., Pickard, A. J., Taylor, B. P., … van den Brink, M. R. M. (2020). The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood, 136(1), 130–136. https://doi.org/10.1182/blood.2019003369

162.

Kaiko, G. E., Ryu, S. H., Koues, O. I., Collins, P. L., Solnica-Krezel, L., Pearce, E. J., … Stappenbeck, T. S. (2016). The colonic crypt protects stem cells from microbiota-derived metabolites. Cell, 167(4), 1137. https://doi.org/10.1016/j.cell.2016.10.034

163.

Golob, J. L., DeMeules, M. M., Loeffelholz, T., Quinn, Z. Z., Dame, M. K., Silvestri, S. S., … Fredricks, D. N. (2019). Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000362

164.

Weber, D., Hiergeist, A., Weber, M., Dettmer, K., Wolff, D., Hahn, J., … Holler, E. (2019). Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: Lack of commensal sparing antibiotics. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 68(8), 1303–1310. Retrieved from https://academic.oup.com/cid/article-abstract/68/8/1303/5075542. Accessed 3 Jan 2022

165.

Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., … Medical Research Council Adult Leukaemia Working Party. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England journal of medicine, 348(19), 1875–1883. https://doi.org/10.1056/NEJMoa022340

166.

Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., … IFM 2009 Study. (2017). Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. The New England journal of medicine, 376(14), 1311–1320. https://doi.org/10.1056/NEJMoa1611750

167.

Khan, N., Peled, J. U., Gomes, A. L. C., Devlin, S. M., Rondon-Clavo, C., Clurman, A., … van den Brink, M. R. M. (2018). Loss of microbiota diversity after autologous stem cell transplant is comparable to injury in allogeneic stem cell transplant. Blood, 132(Supplement 1), 608–608. https://doi.org/10.1182/blood-2018-99-110857

168.

El Jurdi, N., Filali-Mouhim, A., & Salem, I. (2019). … in relative abundance, diversity and richness of the oral and gastrointestinal microbiome during autologous transplantation for multiple myeloma: Results of a …. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. Retrieved from https://www.tctjournal.org/article/S1083-8791(18)31768-3/abstract. Accessed 3 Jan 2022

169.

Vuckovic, S., Minnie, S. A., Smith, D., Gartlan, K. H., Watkins, T. S., Markey, K. A., … Hill, G. R. (2019). Bone marrow transplantation generates T cell-dependent control of myeloma in mice. The Journal of clinical investigation, 129(1), 106–121. https://doi.org/10.1172/JCI98888

170.

Chung, D. J., Pronschinske, K. B., Shyer, J. A., Sharma, S., Leung, S., Curran, S. A., … Young, J. W. (2016). T-cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy. Cancer Immunol Res, 4(1), 61–71. https://doi.org/10.1158/2326-6066.CIR-15-0055

171.

Lu, X., Ding, Z.-C., Cao, Y., Liu, C., Habtetsion, T., Yu, M., … Zhou, G. (2015). Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. Journal of immunology , 194(4), 2011–2021. https://doi.org/10.4049/jimmunol.1401894

172.

Lee, D. H., Fung, T. T., Tabung, F. K., Marinac, C. R., Devore, E. E., Rosner, B. A., … Birmann, B. M. (2020). Prediagnosis dietary pattern and survival in patients with multiple myeloma. International journal of cancer. Journal international du cancer, 147(7), 1823–1830. https://doi.org/10.1002/ijc.32928

173.

Gough, E., Shaikh, H., & Manges, A. R. (2011). Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America, 53(10), 994–1002. https://doi.org/10.1093/cid/cir632CrossRef

174.

DeFilipp, Z., Peled, J. U., Li, S., Mahabamunuge, J., Dagher, Z., Slingerland, A. E., … Chen, Y. B. (2018). Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv, 2(7), 745–753. https://doi.org/10.1182/bloodadvances.2018017731

175.

Taur, Y., Coyte, K., Schluter, J., Robilotti, E., Figueroa, C., Gjonbalaj, M., … Xavier, J. B. (2018). Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Science translational medicine. https://doi.org/10.1126/scitranslmed.aap9489

176.

Kakihana, K., Fujioka, Y., Suda, W., Najima, Y., Kuwata, G., Sasajima, S., … Ohashi, K. (2016). Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 128(16), 2083–2088. https://doi.org/10.1182/blood-2016-05-717652

177.

van Lier, Y. F., Davids, M., Haverkate, N. J. E., de Groot, P. F., Donker, M. L., Meijer, E., … Hazenberg, M. D. (2020). Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. Science translational medicine, 12(556). https://doi.org/10.1126/scitranslmed.aaz8926

178.

Spindelboeck, W., Schulz, E., Uhl, B., Kashofer, K., Aigelsreiter, A., Zinke-Cerwenka, W., … Neumeister, P. (2017). Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease. Haematologica, 102(5), e210–e213. https://doi.org/10.3324/haematol.2016.154351

179.

DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., … Hohmann, E. L. (2019). Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. The New England journal of medicine, 381(21), 2043–2050. https://doi.org/10.1056/NEJMoa1910437

Title: Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation
Authors: Matthew J. Pianko
Jonathan L. Golob
Publication date: 29-04-2022
Publisher: Springer US
Keywords: Multiple Myeloma
Graft-Versus-Host Disease
Respiratory Microbiota
Graft-Versus-Host Disease
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Cancer and Metastasis Reviews / Issue 2/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10033-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Microbes and cancer: disease drivers, passengers, biomarkers, or therapeutics?

Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer

Connecting the Human Microbiome and Pancreatic Cancer

Preface

Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer